E
AVIR icon

Ergoteles’s Atea Pharmaceuticals AVIR Stock Holding History

Ergoteles’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50,500
Closed -$169K – 1048
2023
Q1 		$169K Sell
50,500
-5,531
-10% -$22.4K 0.01% 1040
2022
Q4 		$270K Buy
+56,031
New +$283K 0.01% 950
2021
Q2 		– Sell
-50,362
Closed -$3.11M – 1486
2021
Q1 		$3.11M Buy
+50,362
New +$3.4M 0.1% 226

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's AVIR Position: Q2 2023 in Review

Ergoteles sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 50,500 shares — an estimated $169K sold.

Ergoteles first reported a position in AVIR in Q1 2021 and held it in 3 quarters. The position peaked at $3.11M in Q1 2021. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • Ergoteles reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 50,500 Atea Pharmaceuticals shares in Q2 2023, an estimated $169K.
  • Ergoteles first reported a position in Atea Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Ergoteles's Atea Pharmaceuticals position peaked at $3.11M in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.